2X Oncology Inc., of Cambridge, Mass., said it obtained the investigational new drug application for 2X-111 (doxorubicin hydrochloride and glutathione, formerly 2B3-101) from 2-BBB Medicines BV, of Leiden, the Netherlands, and assumed full ownership and future development of the candidate to treat brain metastases from breast cancer and recurrent glioblastoma multiforme.